Skip to main content

TheraSphere mechanism of action explained

Therasphere Y-90 glass microspheres are uniquely engineered to have unmatched radiation per microsphere (RPM). This allows TheraSphere to maximize repetitive and cumulative radiation exposure to tumor cells to achieve complete pathological necrosis (CPN) at ablative doses. With data since 1999 that spans the BCLC algorithm, TheraSphere is the only FDA approved Y-90 therapy for HCC and is backed by positive level 1 clinical evidence.

TheraSphere is a registered trademark of Theragenics Corporation used under license by Biocompatibles UK Ltd., a wholly owned subsidiary of Boston Scientific Corporation.